Across TCGA pan-cancer cohorts, GAPDHP19 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of GAPDHP19’s most consistent transcriptional readouts.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where GAPDHP19 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP19 is over-expressed in tumor.
LUSC are the cancer types where GAPDHP19 tumor–normal differential expression is most reproducible.